Developments in component therapy: novel components and new uses for familiar preparations

Area of Science:

• Immunohematology
• Transfusion Medicine

Background:

• Blood component transfusions are crucial for treating various diseases and supporting patients, particularly those undergoing chemotherapy.
• Despite advancements, transfusion therapy carries risks including adverse reactions and potential transmission of infectious agents.
• The development of specialized blood components and manufactured products aims to mitigate these risks and meet growing demands.

Purpose of the Study:

• To explore novel applications of common blood components.
• To review emerging and uncommonly used blood components and their therapeutic uses.
• To discuss the origins, composition, and treatment indications for advanced immunohematology products.

Main Methods:

• Review of current literature on blood component therapy.
• Analysis of new and developing blood products and their clinical applications.
• Discussion of specific components: donor leukocyte infusions, dendritic cell vaccines, blood substitutes, novel platelet products, intravenous immunoglobulin (IVIG), and plasma products in therapeutic plasma exchange.

Main Results:

• The study highlights new uses for established blood components and introduces novel products.
• Emerging components include donor leukocyte infusions, dendritic cell vaccines, and blood substitutes.
• Advanced plasma products and novel platelet formulations are also discussed for specific therapeutic applications.

Conclusions:

• The field of immunohematology is rapidly evolving, offering innovative solutions in transfusion medicine.
• Specialized blood components and substitutes are expanding treatment options and improving patient outcomes.
• Continued research and development are essential to address transfusion-related complications and meet clinical needs.